Alwin D R Huitema
Overview
Explore the profile of Alwin D R Huitema including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
394
Citations
4784
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Breekveldt E, Ykema B, Huitema A, Gietema J, Beijnen J, Snaebjornsson P, et al.
PLoS One
. 2024 Nov;
19(11):e0312994.
PMID: 39541403
Testicular cancer survivors (TCS) treated with platinum-based chemotherapy have increased cancer risk. Platinum retention in healthy tissue may contribute to carcinogenesis. We assessed total platinum concentrations in plasma, urine, and...
12.
Almekinders C, Lin L, Beijnen J, Sonke G, Huitema A, Dezentje V
Breast Cancer Res Treat
. 2024 Nov;
210(1):115-124.
PMID: 39508972
Purpose: Palliative treatment options for HR + HER2- advanced breast cancer (ABC) patients have increased, but data is lacking about the optimal treatment sequence. We used real-world data from a...
13.
Damoiseaux D, Beijnen J, Huitema A, Dorlo T
Drug Metab Dispos
. 2024 Oct;
52(11):1217-1223.
PMID: 39362699
Early detection of drug-drug interactions (DDIs) can facilitate timely drug development decisions, prevent unnecessary restrictions on patient enrollment, resulting in clinical study populations that are not representative of the indicated...
14.
Mohlmann J, Ezzafzafi S, Lindemans C, Jansen M, Nierkens S, Huitema A, et al.
Clin Pharmacokinet
. 2024 Sep;
63(9):1251-1270.
PMID: 39264575
Background And Objective: Systemic corticosteroids have a long history of use in the treatment of autoimmune and inflammatory diseases. Both efficacy and safety show large interindividual variability (IIV), suggesting that...
15.
Chu W, Verrest L, Younis B, Musa A, Mbui J, Mohammed R, et al.
J Infect Dis
. 2024 Aug;
230(6):e1375-e1384.
PMID: 39166299
Treatment regimens for post-kala-azar dermal leishmaniasis (PKDL) are usually extrapolated from those for visceral leishmaniasis (VL), but drug pharmacokinetics (PK) can differ due to disease-specific variations in absorption, distribution, and...
16.
Chu W, Nijman M, Stegeman R, Breur J, Jansen N, Nijman J, et al.
Clin Pharmacokinet
. 2024 Aug;
63(8):1205-1220.
PMID: 39147988
Background: The CRUCIAL trial (NCT04217421) is investigating the effect of postnatal and perioperative administration of allopurinol on postoperative brain injury in neonates with critical congenital heart disease (CCHD) undergoing cardiac...
17.
Giraud E, Krens S, Bohringer S, Desar I, Vermeulen S, Kiemeney L, et al.
Br J Clin Pharmacol
. 2024 Aug;
91(2):297-305.
PMID: 39107874
Aims: Sunitinib exhibits considerable interindividual variability in exposure. While the target total plasma concentration of sunitinib and its active metabolite is 50-87.5 ng/mL for the intermittent dosing schedule, ~10-21% of...
18.
Meertens M, Giraud E, van der Kleij M, Westerdijk K, Guchelaar N, Bleckman R, et al.
Clin Pharmacokinet
. 2024 Jul;
63(7):1045-1054.
PMID: 39012619
Introduction And Objective: Pazopanib is registered for metastatic renal cell carcinoma and soft-tissue sarcoma (STS). Its variable pharmacokinetic (PK) characteristics and narrow therapeutic range provide a strong rationale for therapeutic...
19.
Lin L, van der Noort V, Steeghs N, Ruiter G, Beijnen J, Huitema A
Cancer Chemother Pharmacol
. 2024 Jul;
94(3):453-459.
PMID: 38992166
Purpose: In exposure-response analyses of oral targeted anticancer agents, longitudinal plasma trough concentrations are often aggregated into a single value even though plasma trough concentrations can vary over time due...
20.
van der Kleij M, Guchelaar N, Meertens M, Westerdijk K, Giraud E, Bleckman R, et al.
Br J Cancer
. 2024 Jul;
131(5):843-851.
PMID: 38971952
Background: Therapeutic drug monitoring (TDM) - performing dose adjustments based on measured drug levels and established pharmacokinetic (PK) targets - could optimise treatment with drugs that show large interpatient variability...